StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) shareholders

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
6.5%
0M of 2M shares
Institutional holders
8
2 new, 0 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Dmitry Genkin
Joint filing with CLS Therapeutics Ltd. (9.60%), Victor Tets (9.60%) and 2 more
215,964–13D (active) amendmentMar 18, 2024
Renaissance Technologies LLC
Joint filing with Renaissance Technologies Holdings Corporation (6.00%)
137,4406.00%13G (passive) amendmentMar 31, 2026
Michael Liu126,7415.50%13G (passive)May 22, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of XBIOValueChange% of portfolio
Renaissance Technologies LLC117,4405.01%$341.75K−20,0000.00%
Geode Capital Management, LLC17,4230.74%$50.72K−4,0180.00%
Vanguard Capital Management LLC12,6810.54%$36.90K+5,9500.00%
JTC Employer Solutions Trustee Ltd2,7000.12%$8.00K–0.00%
SBI Securities Co., Ltd.1,0000.04%$2.91KNew0.00%
Tower Research Capital LLC (TRC)6960.03%$2.03K−1100.00%
Morgan Stanley1500.01%$437New0.00%
Darwin Wealth Management, LLC20.00%$5–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202680M6.5%2 / 13 / 00M0M
Q1 202660M7.2%1 / 12 / 60M0M
Q4 2025110M9.8%4 / 31 / 30M0M
Q3 2025100M2.5%2 / 21 / 10M0M
Q2 202590M2.7%0 / 22 / 40M0M
Q1 2025130M4.6%1 / 61 / 10M0M
Q4 2024130M3.8%6 / 12 / 20M0M
Q3 202490M2.1%5 / 11 / 10M0M
Q2 202450M0.6%1 / 12 / 30M0M
Q1 202470M0.8%0 / 21 / 00M0M
Q4 202370M0.7%1 / 12 / 10M0M
Q3 202370M0.7%1 / 12 / 30M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held XBIO in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of XBIOValue% of fundAs of
Fidelity Extended Market Index Fund13,7250.59%$42.82K0.00%May 31, 2026
Vanguard Extended Market Index Fund12,6810.54%$36.90K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund2,0700.09%$6.46K0.00%May 31, 2026
Fidelity Series Total Market Index Fund1,3880.06%$4.33K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
James F. ParslowInterim CEO and CFO100,0004.27%Apr 23, 2026
Roger D. KornbergDirector0–Jan 5, 2026
Firdaus J. DastoorDirector––Jan 5, 2026
Grigory G. BorisenkoDirector––Jan 5, 2026
Alexey Andreevich VinogradovDirector186,7817.97%Jan 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
James F. Parslow
Interim CEO and CFO
Apr 21, 2026Award+100,000––100,000
Dmitry Genkin
Director
Jul 19, 2019Award+93,390––93,603
Dmitry Genkin
Director
Mar 14, 2018Other−29,452––2,549
Jeffrey F. Eisenberg
CEO, Director
Oct 26, 2017Award+50,000––50,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.80%
0M shares short
Days to cover
1.2
At 0M shares a day
Change since last report
+237.7%
From 0M shares
Short volume, 20 days
54.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xenetic Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,735 shares on Sep 18, 2026 over the last 90 days.

See a number that looks wrong?